Tempest Therapeutics, Inc. (TPST)
Nasdaq: TPST · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Who owns Tempest Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Matthew Angel holds 37.4% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Mar 25, 2026 says.
Directors and officers
11
report now, of 45 people on the record since 2012. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Matthew Angel
SCHEDULE 13D/A · filed Mar 25, 2026 · Common Stock, par value $0.001 per share · 35.9% in Feb 10, 2026
Sabby Management, LLC
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock
Versant Vantage II, L.P.
SCHEDULE 13D/A · filed Apr 2, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 3.7% in Aug 13, 2025
What TPST reports owning in othersstakes of 5% or more, and other ties
Tempest Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
2purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$1.0Mbought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 65 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President | 0 | $0 | 0 | 2 | $1.0M |